You Position: Home > Paper

The progress of heart failure treatment with sodium-dependent glucose transporters 2 inhibitor

( views:0, downloads:0 )
Author:
No author available
Journal Title:
China Clinical Practical Medicine
Issue:
5
DOI:
10.3760/cma.j.cn115570-20220804-01786-1
Key Word:
No keyword available

Abstract´╝Ü 2021年8月欧洲心脏协会(European Society of Cardiology,ESC)和2022年4月美国心脏协会(American Heart Association,AHA)/美国心脏病学会(American College of Cardiology,ACC)/美国心力衰竭学会(Heart Failure Society of America,HFSA)相继对心力衰竭诊断和治疗指南进行了更新,其中钠-葡萄糖协同转运蛋白-2(sodium-dependent glucose transporters 2 inhibitor,SGLT-2)抑制剂(SGLT-2 inhibition,SGLT-2i)在左室射血分数降低型心力衰竭(heart failure with reduced ejection fraction,HFrEF)、射血分数轻度降低型心力衰竭(heart failure with mildly reduced ejection fraction,HFmrEF)和射血分数保留型心力衰竭(heart failure with preserved ejection fraction,HFpEF)的治疗中均有较高等级推荐。

  • This article has no references!
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn